15.16
price up icon1.34%   0.20
after-market After Hours: 15.08 -0.08 -0.53%
loading

Range Cancer Therapeutics Etf Stock (CNCR) Forecast

The Range Cancer Therapeutics Etf (CNCR) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $17.35, representing a +14.43% increase from the current price of $15.16. The highest analyst price target is $18.99, and the lowest is $15.70.

Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CNCR Price Target
Average 15.91 (+4.95% Upside)
loading

Is Range Cancer Therapeutics Etf (CNCR) A Buy Now?

Oscillators
Name Value Action
RSI(14) 53.50 Neutral
STOCH(9,6) 38.24 Neutral
STOCHRSI(14) 74.72 Neutral
MACD(12,26) -0.00367 Buy
ADX(14) 9.8769 Neutral
William %R -25.64 Neutral
CCI(14) 44.69 Neutral
Buy: 1 Sell: 0 Neutral: 6
Summary: Neutral
Moving Averages
Period Simple Exponential
MA10
14.91
Buy
14.95
Buy
MA20
14.95
Buy
14.95
Buy
MA50
15.00
Buy
14.92
Buy
MA100
14.68
Buy
14.83
Buy
MA200
15.05
Buy
14.35
Buy
Buy: 10 Sell: 0 Neutral: 0
Summary: Buy
According to our latest analysis, CNCR could be considered a Strong Buy, with 17 technical analysis indicators signaling 11 Buy signals, 0 signaling Sell signals and 6 Neutral signals. This might be a good time to open fresh positions on CNCR, as trading bullish markets is always a lot easier
  1. RSI (Relative Strength Index): The RSI(14) value of 53.5 indicates that CNCR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
  2. STOCH (Stochastic Oscillator): The STOCH value of 38.24 indicates that CNCR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
  3. STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 74.72 indicates that CNCR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
  4. ADX (Average Directional Index): The ADX value of The ADX value of 9.8769 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
  5. CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 44.69 indicates that CNCR is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.

Long-term CNCR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050

Based on our analysis about Range Cancer Therapeutics Etf financial reports and earnings history, Range Cancer Therapeutics Etf (CNCR) stock could reach $11.59 by 2030, $1.9585 by 2040 and $2.6909 by 2050. See the projected annual prices until 2050 of the Range Cancer Therapeutics Etf stock below:

  • Range Cancer Therapeutics Etf (CNCR) is expected to reach an average price of $3.6468 in 2035, with a high prediction of $3.6468 and a low estimate of $1.8145. This indicates an $-75.94% rise from the last recorded price of $15.16.
  • Range Cancer Therapeutics Etf (CNCR) stock is projected to chart a bullish course in 2040, with an average price target of $1.4785, representing an $-90.25% surge from its current level. The forecast ranges from a conservative $0.422 to a sky-high $1.9585.
  • Our analysts predict Range Cancer Therapeutics Etf (CNCR) to jump -90.76% by 2045, soaring from $1.4013 to an average price of $1.4013, potentially reaching $1.4388. While $1.4013 is the low estimate, the potential upside is significant.
  • Range Cancer Therapeutics Etf (CNCR) stock is expected to climb by 2050, reaching an average of $3.5409, a $-76.64% jump from its current level. However, a wide range of estimates exists, with high and low targets of $2.6909 and $2.6412, respectively, highlighting the market's uncertainty.

Range Cancer Therapeutics Etf Stock (CNCR) Year by Year Forecast

Range Cancer Therapeutics Etf Stock (CNCR) Price Forecast for 2024

Our forecast for CNCR stock price in 2024 now indicates an average price target of $15.99 with a high forecast of $18.99 and a low forecast of $12.99. The average prediction reflects an increase of +5.50% from the last recorded price of $15.16.
Month Average Low High Change from today's price
December, 2024 $18.75 $15.70 $18.99 +23.71%

Range Cancer Therapeutics Etf Stock (CNCR) Price Forecast for 2025

Range Cancer Therapeutics Etf Stock (CNCR) is expected to reach an average price of $16.47 in 2025, with a high prediction of $25.67 and a low estimate of $7.2788. This indicates an +8.66% rise from the last recorded price of $15.16.
Month Average Low High Change from today's price
January, 2025 $18.44 $18.13 $19.71 +21.66%
February, 2025 $16.30 $16.19 $19.81 +7.52%
March, 2025 $16.44 $16.01 $18.03 +8.42%
April, 2025 $14.82 $7.2788 $18.20 -2.24%
May, 2025 $19.05 $13.99 $19.63 +25.68%
June, 2025 $21.38 $17.06 $21.43 +41.02%
July, 2025 $22.27 $20.27 $23.33 +46.90%
August, 2025 $22.36 $21.92 $23.43 +47.47%
September, 2025 $21.56 $20.49 $23.91 +42.22%
October, 2025 $20.33 $19.38 $22.60 +34.12%
November, 2025 $22.87 $20.22 $24.54 +50.85%
December, 2025 $21.64 $21.60 $25.67 +42.73%

Range Cancer Therapeutics Etf Stock (CNCR) Price Forecast for 2026

The predicted value for Range Cancer Therapeutics Etf (CNCR) in 2026 is set at an average of $26.52. Estimates vary from a peak of $31.31 to a trough of $21.73, indicating an +74.95% surge from the present price of $15.16.
Month Average Low High Change from today's price
January, 2026 $26.98 $21.73 $27.02 +77.98%
February, 2026 $28.66 $27.12 $29.83 +89.06%
March, 2026 $30.12 $26.92 $30.75 +98.71%
April, 2026 $28.81 $27.94 $31.31 +90.03%
May, 2026 $26.76 $23.98 $28.51 +76.54%
June, 2026 $24.23 $23.80 $27.41 +59.84%
July, 2026 $25.23 $23.44 $26.84 +66.43%
August, 2026 $26.79 $24.97 $27.15 +76.70%
September, 2026 $26.96 $25.85 $28.57 +77.82%
October, 2026 $25.10 $23.87 $26.82 +65.59%
November, 2026 $26.18 $22.89 $26.32 +72.69%
December, 2026 $26.57 $25.58 $27.32 +75.26%

Range Cancer Therapeutics Etf Stock (CNCR) Price Forecast for 2027

For 2027, Stockscan's Analyst expects the average price target for Range Cancer Therapeutics Etf (CNCR) is $17.36, with a high forecast of $26.15 and a low forecast of $8.5704. This indicates an +14.53% increase from the last price of $15.16.
Month Average Low High Change from today's price
January, 2027 $24.39 $24.21 $26.06 +60.92%
February, 2027 $23.99 $23.97 $26.15 +58.23%
March, 2027 $21.29 $19.69 $23.73 +40.42%
April, 2027 $16.11 $15.96 $22.36 +6.26%
May, 2027 $14.47 $13.38 $16.28 -4.58%
June, 2027 $12.76 $12.69 $15.40 -15.83%
July, 2027 $13.76 $12.03 $14.54 -9.22%
August, 2027 $11.25 $11.09 $15.12 -25.76%
September, 2027 $9.7169 $8.866 $11.87 -35.90%
October, 2027 $11.42 $8.5704 $11.67 -24.64%
November, 2027 $12.39 $10.48 $12.87 -18.30%
December, 2027 $12.27 $11.23 $13.86 -19.09%

Range Cancer Therapeutics Etf Stock (CNCR) Price Forecast for 2028

In 2028, Range Cancer Therapeutics Etf (CNCR) is projected to reach an average price of $8.4239, with a high projection of $12.72 and a low estimate of $4.1328. This indicates an -44.43% fall from the last price of $15.16.
Month Average Low High Change from today's price
January, 2028 $11.97 $4.1328 $12.72 -21.06%
February, 2028 $10.45 $9.8553 $12.15 -31.04%
March, 2028 $10.44 $9.9415 $11.33 -31.13%
April, 2028 $10.83 $10.14 $11.73 -28.56%
May, 2028 $9.7302 $9.0202 $11.21 -35.82%
June, 2028 $10.88 $9.4234 $11.11 -28.25%
July, 2028 $10.17 $9.8022 $11.14 -32.90%
August, 2028 $8.233 $8.0189 $9.8532 -45.69%
September, 2028 $8.4192 $7.6771 $8.5392 -44.46%
October, 2028 $9.3055 $8.3873 $9.8855 -38.62%
November, 2028 $9.6857 $8.8936 $9.9346 -36.11%
December, 2028 $8.832 $8.592 $10.09 -41.74%

Range Cancer Therapeutics Etf Stock (CNCR) Price Forecast for 2029

The 2029 price forecast for Range Cancer Therapeutics Etf Stock (CNCR) is $9.7696 on average, with a high prediction of $14.18 and a low estimate of $5.355. This represents an -35.56% decrease from the previous price of $15.16.
Month Average Low High Change from today's price
January, 2029 $8.5323 $8.4041 $9.5101 -43.72%
February, 2029 $8.1185 $7.8904 $8.6963 -46.45%
March, 2029 $7.2147 $7.1247 $8.3766 -52.41%
April, 2029 $5.881 $5.881 $7.3288 -61.21%
May, 2029 $6.8012 $5.355 $6.9712 -55.14%
June, 2029 $7.9375 $6.4553 $8.0075 -47.64%
July, 2029 $9.5237 $7.6915 $10.15 -37.18%
August, 2029 $10.82 $9.3318 $10.93 -28.62%
September, 2029 $13.49 $10.40 $13.95 -11.01%
October, 2029 $12.86 $11.99 $14.18 -15.17%
November, 2029 $10.65 $10.03 $12.83 -29.77%
December, 2029 $10.60 $9.7681 $12.09 -30.09%

Range Cancer Therapeutics Etf Stock (CNCR) Price Forecast for 2030

Range Cancer Therapeutics Etf Stock (CNCR) is expected to reach an average price of $8.8021 in 2030, with a high forecast of $15.05 and a low forecast of $2.5577. This signifies an -41.94% decrease from the last price of $15.16.
Month Average Low High Change from today's price
January, 2030 $11.21 $9.5425 $11.59 -26.06%
February, 2030 $11.54 $10.51 $11.96 -23.85%
March, 2030 $10.46 $10.27 $11.92 -30.98%
April, 2030 $9.9767 $9.298 $10.65 -34.19%
May, 2030 $8.6567 $8.1677 $10.72 -42.90%
June, 2030 $10.13 $8.2548 $10.21 -33.19%
July, 2030 $13.83 $10.31 $13.97 -8.78%
August, 2030 $14.26 $13.27 $14.93 -5.92%
September, 2030 $13.84 $13.42 $15.05 -8.68%
October, 2030 $13.02 $11.44 $14.17 -14.12%
November, 2030 $8.2717 $2.5577 $13.47 -45.44%
December, 2030 $11.57 $7.8758 $11.57 -23.68%
exchange_traded_fund VTV
$173.57
price up icon 1.06%
exchange_traded_fund VUG
$390.21
price up icon 1.38%
exchange_traded_fund IJH
$63.10
price up icon 1.45%
exchange_traded_fund EFA
$80.23
price up icon 0.99%
exchange_traded_fund IWF
$380.80
price up icon 1.39%
exchange_traded_fund QQQ
$492.21
price up icon 1.28%
Cap:     |  Volume (24h):